Browsing by Subject "ccRCC"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Deregulation and delocalization of the m6A demethylase FTO and aberrant m6A levels in ccRCC tissue samples
    (Universidad de Murcia, Departamento de Histología e Histopatología, 2025) Tito Claudia; Rosa Paolo; Sorrentino Veronica; Magnanti Martina; Innocenti Angelica; Zaccaria Lorenzo; Costantini Manuela; Laiza Alessia; Bastianelli Daniela; Masciarelli Silvia; Pastore Antonio Luigi; Simone Giuseppe; Carbone Antonio; Fatica Alessandro; Petrozza Vincenzo; Fazi Francesco; Biología Celular e Histología
    N6-methyladenosine (m6A) is one of the most abundant mRNA modifications established by the activity of three classes of enzymes: writers, readers, and erasers. The relevance of m6A in the regulation of gene expression implies its key role in normal biological processes and cancer development. Given the little knowledge about the involvement of m6A in clear cell Renal Carcinoma (ccRCC), our analysis should be regarded as a pilot study aimed at investigating the expression of m6A enzymes in tissues and urine specimens of ccRCC patients. The expression of m6A enzymes was validated by quantitative reverse-transcription PCR and immuno-histochemistry, comparing normal and tumoral tissues. Quantification of m6A levels in urine specimens of healthy and cancer patients was performed by colorimetric Urine m6A assay. We observed the upregulation and nuclear localization of the m6A demethylase FTO in tumoral tissues compared with their respective normal counterparts. The nuclear expression of FTO decreases with an increase in tumor grade. Moreover, we identified a decrease in m6A levels in cancer samples. These findings might represent novel evidence to further investigate the issue, to reveal new diagnostic markers for tumorigenesis, leading to a potential m6A-targeted therapy in ccRCC
  • Thumbnail Image
    Publication
    Open Access
    Long non-coding RNA BRE-AS1 inhibits proliferation, migration and invasion of clear cell renal cell carcinoma by downregulating miR-106b-5p
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Zou, Gaode; Guo, Lian; Shen, Shaochen; Song, Zhen; Ouyang, Zheying; Yu, Yi
    Objective. The objective of this study was to investigate the involvement of the long non-coding RNA (lncRNA) BRE-AS1 in clear cell renal cell carcinoma (ccRCC) and to explore its potential therapeutic role. Methods. The expression of BRE-AS1 and miR-106b-5p was determined by qRT-PCR. Overexpression of BRE-AS1 and miR-106b-5p were performed to study their relationship. Transwell assays were used to evaluate cell movement. Methylation-specific PCR (MSP) was performed to explore the role of BRE-AS1 in the methylation of the miR-106b-5p gene. Results. The results showed that the expression levels of BRE-AS1 were decreased, while those of miR-106b-5p were increased in ccRCC tissues. BRE-AS1 was found to be closely associated with the prognosis of patients with ccRCC. The expression of BRE-AS1 was inversely correlated with that of miR-106b-5p in tumor tissues. Overexpression of BRE-AS1 led to decreased expression levels of miR-106b-5p and increased methylation of the miR-106b-5p gene, whereas miR-106b-5p did not affect the expression of BRE-AS1. BRE-AS1 inhibited the movement and proliferation of ccRCC cell lines, while miR-106b-5p suppressed the role of BRE-AS1. Conclusion. BRE-AS1 may suppress ccRCC by downregulating the expression of miR-106b-5p.